Re: Farmas USA
RDUS
Cantor: (Overweight, PT $58).have updated model and addressed 4Q17 revenue estimate, lowering it to $5.4 mln from $8.9 mln. still see growing TYMLOS prescriptions as positive, and while like opportunity overall, we do expect that the launch could be bumpy
Ventas bastante pobres las que se esperan...